Yazarlar : Groenendaal G, van Vulpen M, Pereboom SR, Poelma-Tap D, Korporaal JG, Monninkhof E, van der Heide UA.
Yayın : Radiother Oncol.
Yayın Yılı : 2012
Pubmed Linki : http://www.ncbi.nlm.nih.gov/pubmed/22265733
Konu : Radyasyon Onkolojisi
Literatür İçeriği :
Abstract
BACKGROUND AND PURPOSE:
For focal boosting of prostate tumors, three questions are important regarding the use of hormonal therapy. Does prolonged hormonal treatment affect the conspicuity of tumor tissue on diffusion weighted imaging (DWI) and dynamic contrast-enhanced (DCE-MRI) images? Is tumor delineation possible in patients using hormonal treatment? Can we identify specific imaging thresholds for tumor delineation in patients after prolonged androgen deprivation?
MATERIALS AND METHODS:
Ninety-six patients were included. Using multivariate linear regression analyses, we investigated if DWI and DCE-MRI parameter maps are different in patients receiving hormonal treatment for 0-3 or >3months. Furthermore, logistic regression was performed to obtain specific imaging thresholds for tumor tissue for the two patient groups.
RESULTS:
We found a significantly higher diffusion and lower perfusion of tumor tissue in the >3months hormonal treatment group compared to the 0-3 group. This resulted in lower tumor conspicuity. Nevertheless, in 18/21 of the patients in the >3months treatment group, a suspicious lesion could be defined based on the MR images. Based on logistic regression, different imaging thresholds should be set for tumor detection in the two treatment groups.
CONCLUSIONS:
Prolonged androgen deprivation decreases tumor conspicuity. Different imaging thresholds need to be set to delineate tumor in patients who have had prolonged hormonal treatment.
Sunumlar | Videolar | Olgu Tartışması |